MedWatch

Lundbeck initiates two phase III studies with its main growth driver

Danish drug group Lundbeck and its Japanese partner Otsuka have started enrolling patients in two global phase III studies with the major engine of growth in the Danes’ new drugs portfolio. But neither analysts nor Lundbeck itself attach much importance to the development.

Photo: Lundbeck / PR

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try us for 14 days

Try a trial subscription for access to our quality journalism

Frontpage right now

FDA vil lette vejen til markedet for medicin mod Alzheimers

De amerikanske lægemiddelmyndigheder vil lempe kravene til godkendelse af lægemidler mod Alzheimers, fordi forskning viser, at sygdommen indtræder tidligere end hidtil antaget. Lægemiddeludviklingen og godkendelse heraf derfor skal tilpasses derefter, mener FDA-boss Scott Gottlieb.

Related articles